[Correspondence] Reassessing the 1  + 1 pneumococcal conjugate vaccine schedule

Pneumococcal conjugate vaccines (PCVs) are approved and given to populations on the basis of large immunogenicity and safety databases after meeting strict prespecified immunological non-inferiority criteria in appropriately powered clinical studies. David Goldblatt and colleagues1 describe the response to a single dose of PCV in the first year of life followed by a booster in the second year (1  + 1 schedule), and compare this to the standard 2 + 1 schedule. Based on previous experience in the clinical setting, the results were not surprising.
Source: The Lancet Infectious Diseases - Category: Infectious Diseases Authors: Tags: Correspondence Source Type: research